Market news

Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate

2026-09-24. The following slide deck was published by Cue Biopharma, Inc.

Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.

Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock moved upwards

Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria.

Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applicationsCompleted a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for value-inflectionStrengthened the leadership team with the appointments of the Chief Medical Officer and Head of R&D and the Chief Financial OfficerOperating results reflected higher expenditures related to the licensing and initiation of the CUE-221 devel

Detailed price information for Cue Biopharma Inc (CUE-Q) from The Globe and Mail including charting and trades.

Cue Biopharma (CUE) said Monday it appointed James Ahlers as chief financial officer. The company

Veteran biotech finance executive joins Cue to support the Company’s next phase of clinical and corporate growth as the company advances regulatory filing for food allergyBOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer. Mr. Ahlers will report to President and Chief Executive Officer S

Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseasesBOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. He reports to President and Chief Executive Officer Shao-L

BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of $33.21 per share and (ii) to certain investors, in lieu of shares of common st